natgillin/translations-raw huggingface dataset:
Oslif Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Zdravilo Oslif Breezhaler ni indicirano za zdravljenje akutnih epizod bronhospazma, t.j. kot zdravilo za nujne primere.
Oslif Breezhaler is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Zdravilo Oslif Breezhaler se uporablja za vzdrževanje odprtih dihalnih poti pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Oslif Breezhaler must not be used in people who are hypersensitive (allergic) to indacaterol, lactose or any of the other ingredients.
Zdravila Oslif Breezhaler ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) indakaterol, laktozo ali katero koli drugo sestavino zdravila.
Oslif Breezhaler should not be given to children or adolescents below the age of 18 years
Otroci in mladostniki, ki so stari manj kot 18 let, ne smejo prejemati zdravila Oslif Breezhaler.
Oslif Breezhaler should not be used in asthma due to the absence of long-term outcome data in asthma with Oslif Breezhaler.
da se zdravila Oslif Breezhaler ne sme uporabljati pri astmi, ker ni podatkov o dolgoročnih rezultatih pri zdravljenju astme z zdravilom Oslif Breezhaler,
Osmolality (37°C): 1000 – 1200 mOsm/kg
Osmolalnost (37 °C): 1000–1200 mOsm/kg
Osmolality:
Osmolarnost :
Ospemifene and its major metabolite, 4-hydroxyospemifene, are metabolised by multiple metabolic pathways, the main enzymes involved are UGT1A3, UGT2B7, UGT1A1 and UGT1A8, and CYP2C9, CYP3A4 and CYP2C19.
Ospemifen in njegov glavni presnovek, 4-hidroksiospemifen, se presnavljata po več presnovnih poteh, pri čemer so glavni encimi, ki so vključeni v presnovo UGT1A3, UGT2B7, UGT1A1 in UGT1A8 ter CYP2C9, CYP3A4 in CYP2C19.
Ospemifene belongs to a group of medicines that do not contain hormones called Selective Estrogen Receptor Modulators (SERMs).
Ospemifene sodi v skupino zdravil, ki ne vsebujejo hormonov, imenovanih selektivni modulatorji estrogenskih receptorjev (SERM, selective estrogen receptor modulators).
Ospemifene exhibits linear pharmacokinetics in the fed state within the dose range of 60 mg to 240 mg.
Ospemifen kaže ob zaužitju s hrano linearno farmakokinetiko znotraj razpona odmerkov od 60 mg do 240 mg.
Ospemifene has been administered to subjects in single doses for up to 800 mg day and repeat doses up to 240 mg/day for 7 days and up to 200 mg/day for 12 weeks.
Ospemifen so dajali osebam v enkratnih odmerkih do 800 mg na dan ter v ponavljajočih odmerkih do 240 mg/dan 7 dni in do 200 mg/dan 12 tednov.
Ospemifene improved post-menopausal physiologic changes.
Ospemifen je izboljšal fiziološke spremembe po menopavzi.
Ospemifene is absorbed rapidly after oral administration, with a Tmax of approximately 3 - 4 hours post-dose in the fed state.
Ospemifen se po peroralnem dajanju s hrano hitro absorbira s Tmax približno 3–4 ure po odmerku.
Ospemifene is highly (>99%) bound to serum proteins.
Ospemifen se močno (> 99%) veže na serumske beljakovine.
Ospemifene’s biological actions are mediated through the binding of ospemifene and its major metabolite to oestrogen receptors.
Pri biološkem delovanju ospemifena sodeluje vezava ospemifena in njegovega glavnega presnovka na estrogenske receptorje.
OSSEOR 2 g granules for oral suspension
OSSEOR 2 g zrnca za peroralno suspenzijo
OSSEOR contains aspartame, a source of phenylalanine, which may be harmful for people with phenylketonuria.
Zdravilo OSSEOR vsebuje aspartam, vir fenilalanina, ki je lahko škodljiv za bolnike s fenilketonurijo.
OSSEOR is a medicine used to treat severe osteoporosis:
OSSEOR je zdravilo za zdravljenje hude osteoporoze:
OSSEOR is available in sachets containing yellow granules for oral suspension.OSSEOR is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.
OSSEOR je na voljo v vrečkah, ki vsebujejo rumena zrnca za peroralno suspenzijo Škatle zdravila OSSEOR vsebujejo 7, 14, 28, 56, 84 ali 100 vrečk.
OSSEOR is contraindicated and must not be used in patients with :
Zdravilo OSSEOR je kontraindicirano in se ne sme predpisovati bolnikom:
OSSEOR is not intended for use in children and adolescents (below the age of 18).
Zdravilo OSSEOR ni namenjen otrokom in mladostnikom (mlajšim od 18 let).
OSSEOR is only indicated for use in patients with severe osteoporosis at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
Zdravilo OSSEOR je indicirano samo za zdravljenje bolnikov s hudo osteoporozo z velikim tveganjem za zlome, pri katerih zdravljenje z drugimi zdravili, ki so odobrena za zdravljenje osteoporoze, zaradi kontraindikacij ali neprenašanja ni mogoče.
Osseor is unlikely to affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo OSSEOR vplivalo na vašo sposobnost upravljanja vozil in strojev.
OSSEOR should only be used with caution in:
Zdravilo OSSEOR je potrebno uporabljati previdno pri:
Ostenfelder Strasse 51-61 D-59320 Ennigerloh Germany
Ostenfelder Strasse 51-61 D-59320 Ennigerloh Nemčija
Osteoarthrit is, myalgia, arthralgia, joint disorder, bone pain
, mialgija, artralgija, bolezen sklepov, bolečina v kosteh
Osteoarthritis, myalgia, arthralgia, joint disorder, bone pain
osteoartritis, mialgija, artralgija, bolezen sklepov, bolečina v kosteh
Osteocalcin increased;
zvišanje ravni osteokalcina,
Osteogenic cells
Osteogene celice
Osteomalacia (manifested as bone pain and infrequently contributing to fractures) and myopathy, both associated with proximal renal tubulopathy
osteomalacija (ki se kaže kot bolečine v kosteh in redko prispeva k zlomom) in miopatija, obe povezani s proksimalno ledvično tubulopatijo
osteomalacia (manifested as bone pain and infrequently contributing to fractures)2,4, myopathy2
osteomalacija (ki se kaže kot bolečine v kosteh in redko prispeva k zlomom)2,4, miopatija4
osteomalacia (manifested as bone pain and infrequently contributing to fractures)3, 5, 8, myopathy3, 5
osteomalacija (ki se kaže kot bolečine v kosteh in redko prispeva k zlomom)3, 5, 8, miopatija3, 5
Osteomyelitis
osteomielitis
Osteonecro sis of jaw†** Osteonecro sis of the external auditory canal (bisphosph onate class adverse reaction)†
osteonekroza čeljustnic†** osteonekroza zunanjega slušnega kanala (neželeni učinek na bisfosfonate)
Osteonecrosis of jaw
Osteonekroza čeljustnic
Osteonecrosis of jaw*†
osteonekroza čeljustnic
Osteonecrosis of jaw*† Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)†
osteonekroza čeljustnic*† osteonekroza zunanjega slušnega kanala (neželeni učinek na bisfosfonate)
Osteonecrosis of jaw†** Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)†
osteonekroza čeljustnic†**, osteonekroza zunanjega sluhovoda (neželeni učinek skupine difosfonatov)
Osteonecrosis of jaw†**, osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)
osteonekroza čeljustnic†**, osteonekroza zunanjega slušnega kanala (neželeni učinek skupine bisfosfonatov)
Osteonecrosis of jaw†*, osteonecrosis of the external auditory canal (bisphosphona te class adverse reaction)†
osteonekroza čeljustnic†*, osteonekroza zunanjega sluhovoda (neželeni učinek skupine difosfonatov)
Osteonecrosis of the external auditory
Osteonekroza zunanjega slušnega
Osteonecrosis of the external auditory
Osteonekroza zunanjega slušnega kanala
osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)
osteonekroza zunanjega slušnega kanala (neželeni učinek skupine bisfosfonatov)
Osteonecrosis of the jaw (ONJ)
Osteonekroza čeljustnic
Osteonecrosis of the Jaw (ONJ)
osteonekroza čeljustnic (ONČ)
Osteonecrosis of the jaw (ONJ)
Osteonekroza čeljustnice
Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post marketing setting in patients receiving zoledronic acid.
O osteonekrozi čeljusti (ONJ) so občasno poročali pri bolnikih, ki so prejemali zoledronsko kislino v kliničnih preskušanjih ali so se z njim zdravili po začetku trženja zdravila.
Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post- marketing setting in patients receiving zoledronic acid.
O osteonekrozi čeljustnic so občasno poročali v kliničnih preskušanjih in po začetku trženja zdravila pri bolnikih, ki so prejemali zoledronsko kislino.
Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post-marketing setting in patients receiving zoledronic acid.
O osteonekrozi čeljustnic (ONČ) so občasno poročali pri bolnikih, ki so prejemali zdravilo Zoledronska kislina Actavis v kliničnih preskušanjih ali so se z njim zdravili po začetku trženja zdravila.
Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post-marketing setting in patients receiving zoledronic acid.
O osteonekrozi čeljustnic so občasno poročali v kliničnih preskušanjih in po začetku trženja zdravila pri bolnikih, ki so prejemali zoledronsko kislino.
Osteonecrosis of the jaw (see
osteonekroza čeljusti (glejte poglavji 4.4 in
Osteonecrosis of the jaw (see sections
osteonekroza čeljusti (glejte poglavji 4.4
Osteonecrosis of the jaw (see sections 4.4
osteonekroza čeljusti (glejte poglavji 4.4
Osteonecrosis of the jaw has multiple well documented risk factors including a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, anti-angiogenic medicinal products, radiotherapy, corticosteroids) and co-morbid conditions (e.g. anaemia, coagulopathies, infection, pre-existing dental disease).
Osteonekroza čeljusti ima številne dobro dokumentirane dejavnike tveganja, ki vključujejo diagnozo raka, sočasno zdravljenje (npr. kemoterapijo, antiangiogena zdravila, radioterapijo, kortikosteroide) in sočasna bolezenska stanja (npr. anemijo, koagulopatije, infekcijo, predhodno bolezen zob).
Osteonecrosis of the jaw is generally associated with tooth extraction and/or local infection (including osteomyelitis).
Osteonekroza čeljustnic je navadno povezana z izdrtjem zoba ali lokalno okužbo (vključno z osteomielitisom) ali obojim.
Osteonecrosis of the jaw(ONJ) has been reported very rarely in the post marketing setting in patients receiving ibandronic acid for oncology indications (see section 4.8).
Pri bolnikih, ki so prejemali ibandronsko kislino za onkološke indikacije, so v obdobju po začetku trženja v zelo redkih primerih poročali o osteonekrozi čeljustnice (glejte poglavje 4.8).
Osteonecrosis of the jaw(ONJ) has been reported very rarely in the post marketing setting in patients receiving ibandronic acid for osteoporosis (see section 4.8).
Pri bolnikih, ki so prejemali ibandronsko kislino za onkološke indikacije, so v obdobju po začetku trženja v zelo redkih primerih poročali o osteonekrozi čeljustnice (glejte poglavje 4.8).
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis), has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphosphonates.
Pri bolnikih z rakom, ki so prejemali zdravljenje, ki je prvenstveno vključevalo difosfonate, dane intravensko, so poročali o osteonekrozi čeljustnic, po navadi povezani z izdrtjem zoba ali lokalno okužbo (vključno z osteomielitisom) ali obojim.
Osteonecrosis of the jaw1
osteonekroza čeljustnice1
osteonecrosis of the jaw‡§; atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)
osteonekroza čeljusti‡§, atipični subtrohanterni zlomi stegnenice in zlomi diafize stegnenice (za bisfosfonate značilen neželeni učinek)
Osteonecrosis: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy).
Osteonecrosis: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV–disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredujočo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
Osteonecrosis: although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
Osteoporosis
osteoporoza
osteoporosis (bone disease), sickle cell anaemia, as filgrastim may cause sickle cell crisis.
osteoporozo (bolezen kosti), srpastocelično anemijo, saj lahko filgrastim povzroči srpastocelično krizo.
osteoporosis (bone disease), sickle cell disease anaemia, as filgrastim can cause sickle cell crisis.
osteoporozo (bolezen kosti), srpastocelično anemijo, saj lahko filgrastim povzroči srpastocelično krizo.
osteoporosis (bone disease); sickle cell anaemia, as Filgrastim HEXAL may cause sickle cell crisis.
osteoporozo (bolezen kosti). srpastocelično anemijo, saj lahko zdravilo Filgrastim HEXAL povzroči srpastocelično krizo.
osteoporosis (bone disease); sickle cell anaemia, as Zarzio may cause sickle cell crisis.
osteoporozo (bolezen kosti). srpastocelično anemijo, saj lahko zdravilo Zarzio povzroči srpastocelično krizo.
osteoporosis (loss of bone density) alcoholism
osteoporoza (zmanjšanje mineralne gostote kosti); alkoholizem.
osteoporosis in women after the menopause (postmenopausal) and men who have an increased risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures. bone loss that results from a reduction in hormone (testosterone) level caused by surgery or treatment with medicines in patients with prostate cancer.
osteoporozo pri ženskah po menopavzi (postmenopavzalno) in moških, ki imajo povečano tveganje zlomov (zlomljenih kosti), tako da se zmanjša tveganje zlomov hrbtenice, nehrbteničnih zlomov in zlomov kolka. izgubljanje kostne mase, ki nastane zaradi manjše koncentracije hormonov (testosterona) kot posledica operacije ali zdravljenja z zdravili pri bolnikih z rakom na prostati.
Osteoporosis/osteopen ia, arthralgia, muscular weakness, muscle spasms, joint swelling/stiffness
osteoporoza/os teopenija, artralgija, šibkost mišic, mišični spazmi, otekanje/otrdel ost sklepov
Osteoporosis/osteopenia, arthralgia muscular weakness, muscle spasms, joint swelling/stiffness
osteoporoza/osteop enija, artralgija, šibkost mišic, mišični spazmi, otekanje/otrdelost sklepov
Osteosarcomas, a known effect of bone-seeking radionuclides, were observed at clinically relevant doses in rats 7 – 12 months after start of treatment.
Osteosarkom, znan učinek radionuklidov, ki se nalagajo v kosteh, so pri podganah opazili 7–12 mesecev po začetku zdravljenja s klinično pomembnimi odmerki.
OSURNIA ear gel for dogs is available in the following pack sizes: 1 carton box containing 2 tubes,
OSURNIA gel za uho za pse je na voljo v naslednjih velikostih pakiranja: Ena kartonska škatla, ki vsebuje 2 tubi.
otalol (for heart disorders) ritonavir (anti-HIV medicine). medicines known to affect the way your heart beats (drugs that prolong the QT interval).
otalol (za srčne motnje), ritonavir (zdravljenje okužbe s HIV). zdravila, za katera je znano, da vplivajo na bitje vašega srca (zdravila, ki podaljšajo interval QT).
Otezla 10 mg film-coated tablets Otezla 20 mg film-coated tablets Otezla 30 mg film-coated tablets
Otezla 10 mg filmsko obložene tablete Otezla 20 mg filmsko obložene tablete Otezla 30 mg filmsko obložene tablete
Otezla 30 mg film–coated tablets apremilast
Otezla 30 mg filmsko obložene tablete apremilast
Otezla contains the active substance ‘apremilast’.
Zdravilo Otezla vsebuje zdravilno učinkovino ‘apremilast’.
Otezla has also been shown to improve the quality of life in patients with psoriasis or psoriatic arthritis.
Prav tako se je izkazalo, da zdravilo Otezla pri bolnikih s psoriazo ali psoriatičnim artritisom izboljšuje kvaliteto življenja.
Otezla has no effect on the ability to drive and use machines.
Zdravilo Otezla ne vpliva na sposobnost upravljanja vozil in strojev.
Otezla is used to treat adults with the following conditions:
Zdravilo Otezla uporabljamo za zdravljenje odraslih z naslednjimi stanji:
Otezla should be dose reduced to 30 mg once daily in patients with severe renal impairment (see sections 4.2 and 5.2).
Pri bolnikih s hudo okvaro ledvic morate odmerek zdravila Otezla zmanjšati na 30 mg enkrat na dan (glejte poglavji 4.2 in 5.2).
Otezla works by reducing the activity of an enzyme in the body called ‘phosphodiesterase 4’, which is involved in the process of inflammation.
Zdravilo Otezla deluje tako, da v telesu zmanjšuje aktivnost encima, ki se imenuje ‘fosfodiesteraza 4’ in je vpleten v proces vnetja.
Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1).
Zdravilo Otezla, samo ali v kombinaciji z antirevmatičnimi zdravili, ki modificirajo bolezen (DMARDs - Disease Modifying Antirheumatic Drugs ), je indicirano za zdravljenje aktivnega psoriatičnega artritisa (PsA) pri odraslih bolnikih, ki so se nezadostno odzvali na predhodno zdravljenje z DMARD ali ga niso prenašali (glejte poglavje 5.1).
Othe r me dicines and Mimpara
Druga zdravila in zdravilo Mimpara
Othe r me dicines and Sabe rvel
Druga zdravila in zdravilo Sabe rvel
OTHER
0,48
OTHER
0,49
OTHER
ANNAÐ
OTHER
OSTALI PODATKI
OTHER
ŠKATLA
OTHER (FOR CALENDARISED PACKS)
DRUGI PODATKI (ZA KOLEDARSKA PAKIRANJA)
Other (N=252)
1.0 1.0
Other 1 0
Drugo 1 0
Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Tivicay.
Druga zdravila za zmanjševanje kisline, kot so ranitidin in omeprazol, se lahko jemljejo sočasno z zdravilom Tivicay.
Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Triumeq.
Druga zdravila za zmanjševanje kisline, kot so ranitidin in omeprazol, se lahko jemljejo sočasno z zdravilom Triumeq.
Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL- 1 beta gene, initiating a gouty arthritis attack.
V transkripcijsko aktivacijo gena za IL-1 beta, ki sproži napad uričnega artritisa, so lahko vpleteni tudi drugi aktivatorji prirojenega imunskega sistema, kot so endogeni agonisti "toll- like" receptorjev.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Druge zdravilne učinkovine, kot so cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko vstopajo v interakcijo z memantinom, kar lahko poveča tveganje za porast plazemske vrednosti.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale zdravilne učinkovine, kot cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko interagirajo z memantinom, kar vodi v možnost zvišane plazemske vrednosti.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale zdravilne učinkovine, kot cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko medsebojno reagirajo z memantinom, kar lahko vodi do zvišanih vrednosti v plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale zdravilne učinkovine, kot so cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko medsebojno reagirajo z memantinom, kar lahko vodi do povišanih vrednosti v plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale zdravilne učinkovine, kot cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko interagirajo z memantinom, kar vodi v možnost zvišane plazemske vrednosti.